Uno studio su JNJ-78278343, un agente di reindirizzamento delle cellule T che prende di mira la callicreina umana 2 (KLK2), per il cancro alla prostata avanzato
Uno studio di fase 1 su JNJ-78278343, un agente di reindirizzamento delle cellule T mirato alla callicreina umana 2 (KLK2), per il carcinoma prostatico avanzato
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Beijing, Cina, 100191
- Peking University Third Hospital
-
Chongqing, Cina, 400030
- Chongqing University Cancer Hospital
-
Guangzhou, Cina, 510710
- Sun Yat Sen University Cancer Center
-
Wenzhou, Cina, 325399
- First Affiliated Hospital Of Wenzhou Medical College
-
-
-
-
-
Lyon, Francia, 69373
- Centre Leon Berard
-
Marseille, Francia, 13005
- APHM Hopital Timone
-
Villejuif, Francia, 94800
- Institut Gustave Roussy
-
-
-
-
-
Kashiwa, Giappone, 277 8577
- National Cancer Center Hospital East
-
Yokohama, Giappone, 232 0024
- Yokohama City University Medical Center
-
-
-
-
-
Amsterdam, Olanda, 1066 CX
- Antoni van Leeuwenhoek
-
Rotterdam, Olanda, 3015 GD
- Erasmus MC
-
-
-
-
-
Madrid, Spagna, 28040
- Hosp Univ Fund Jimenez Diaz
-
Madrid, Spagna, 28050
- Hosp Univ Hm Sanchinarro
-
Málaga, Spagna, 29010
- Hosp Virgen de La Victoria
-
-
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10032
- Columbia University Medical Center Herbert Irving Pavilion
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195-9472
- University of Washington
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Confirmed adenocarcinoma of the prostate which has spread to other body parts
- Part 1: Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy
- Measurable or evaluable disease
- Concurrent use of any other anticancer treatment must be discontinued for at least 2 weeks before the first dose of study drug
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Prior surgical removal of testicles; or, for participants who have not undergone surgical removal of testicles, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog
Exclusion Criteria:
Disease conditions
- Active central nervous system (CNS) involvement
- Toxicity related to prior anticancer therapy has not adequately recovered
Prior/Concomitant Therapy
- Prior treatment with human kallikrein (KLK) 2-targeted therapy
- Received, or are receiving, medications that suppress the immune system within 3 days prior to the first dose of study drug
- Received or plans to receive any live, attenuated vaccine within 4 weeks prior to the first dose of study drug
Prior/Concurrent Medical Conditions
- Diagnosis of cancer other than prostate cancer within 2 years prior to the first dose of study drug
- Solid organ or bone marrow transplantation
- Major clotting diseases within one month prior to the first dose of study drug
- Active autoimmune disease within 12 months prior to the first dose of study drug
- Active infection
- Major diseases of heart and blood vessels within 6 months prior to the first dose of study drug
- Clinically significant lung diseases
- Active or chronic hepatitis B or hepatitis C infection
- Known positive test result for human immunodeficiency virus (unless stable on antiretroviral therapy with undetectable viral load)
- Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: JNJ-78278343
Participants will receive JNJ-78278343. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 at recommended phase 2 dose (RP2D) as determined in Part 1. Participants who are still on study treatment (i.e., who are in Treatment Phase) at the time of the long term extension (LTE) will continue to receive study treatment until they reach a reason for discontinuation of treatment or until further notification by the sponsor of a different means for continued supply of study treatment, whichever occurs first. |
JNJ-78278343 will be administered. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1 and 2: Number of Participants With Adverse Events (AEs)
Lasso di tempo: Up to 1 year and 10 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to 1 year and 10 months
|
|
Part 1 and 2: Number of Participants With AEs by Severity
Lasso di tempo: Up to 1 year and 10 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. |
Up to 1 year and 10 months
|
|
Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Lasso di tempo: Up to 1 year and 10 months
|
Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 1 year and 10 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Serum Concentration of JNJ-78278343
Lasso di tempo: Up to 1 year and 10 months
|
Serum concentrations of JNJ-78278343 will be determined. |
Up to 1 year and 10 months
|
|
Systemic Cytokine Concentrations
Lasso di tempo: Up to 1 year and 10 months
|
Cytokine concentrations will be determined for biomarker assessment. |
Up to 1 year and 10 months
|
|
Serum Prostate Specific Antigen (PSA) Concentration
Lasso di tempo: Up to 1 year and 10 months
|
Serum PSA concentration will be measured. |
Up to 1 year and 10 months
|
|
Number of Participants With Anti-JNJ-78278343 Antibodies
Lasso di tempo: Up to 1 year and 10 months
|
Serum samples will be analyzed for the detection of anti-JNJ-78278343 antibodies using a validated assay method. |
Up to 1 year and 10 months
|
|
Objective Response Rate (ORR)
Lasso di tempo: Up to 1 year and 10 months
|
ORR is defined as the percentage of participants who have a partial response (PR) or better according to the response evaluation criteria in solid tumors (RECIST) version 1.1 response criteria without evidence of bone progression according to prostate cancer working group 3 (PCWG3). |
Up to 1 year and 10 months
|
|
Radiographic Progression-free Survival (rPFS)
Lasso di tempo: Up to 1 year and 10 months
|
rPFS is defined as time from the date of first dose of JNJ-78278343 until the date of objective disease progression or death, whichever comes first. |
Up to 1 year and 10 months
|
|
PSA Response Rate
Lasso di tempo: Up to 1 year and 10 months
|
PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline. The maximum reduction from baseline in PSA will also be calculated during the treatment. |
Up to 1 year and 10 months
|
|
Duration of Response (DOR)
Lasso di tempo: Up to 1 year and 10 months
|
DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first. |
Up to 1 year and 10 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CR108958
- 2020-005970-83 (Numero EudraCT)
- 78278343PCR1001 (Altro identificatore: Janssen Research & Development, LLC)
- 2023-506585-31-00 (Identificatore di registro: EUCT number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .